Pharmaids Pharmaceuticals (524572) Q1 24/25 earnings summary

Executive summary

• Board approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2024, following audit committee review.

• Financials prepared in compliance with Ind AS and SEBI regulations.

Financial highlights

• Standalone revenue from operations was ₹16.65 lakhs, up from ₹0.70 lakhs in the previous quarter and ₹2.78 lakhs year-over-year.

• Standalone net loss for the quarter was ₹162.34 lakhs, compared to a loss of ₹223.71 lakhs in the previous quarter and ₹130.03 lakhs year-over-year.

• Consolidated revenue from operations was ₹467.46 lakhs, down from ₹580.59 lakhs in the previous quarter and from ₹1,511.21 lakhs year-over-year.

• Consolidated net loss for the quarter was ₹312.45 lakhs, compared to a loss of ₹632.65 lakhs in the previous quarter and ₹130.04 lakhs year-over-year.

Outlook and guidance

• The company continues to operate in the Contract Research and Manufacturing Services segment.